, Volume 49, Supplement 2, pp 152–158 | Cite as

Veterinary Use of New Quinolones in Japan

  • Shinichi Nakamura
State-Of-The-Art Presentations


Five new quinolones are used as veterinary medicines in Japan. Benofloxacin and ofloxacin are orally given in feed or in drinking water for respiratory diseases due to Mycoplasma spp. and Escherichia coli in poultry. Enrofloxacin is subcutaneously, intramuscularly or orally administered to cattle and swine for pneumonia due to Pasteurella spp., Mycoplasma spp. and Actinobacillus pleuropneumoniae and diarrhoea due to E. coli, and is used orally for respiratory diseases in poultry. Danofloxacin is similar to enrofloxacin except that the former is not approved for diarrhoea in cattle and swine. Orbifloxacin is given intramuscularly for pneumonia and diarrhoea in cattle and swine but not for poultry diseases. They are effective and safe in animals, and disappear from edible tissues after appropriate drug withdrawal times. The quinolones are indicated only when first-choice drugs are ineffective, only under the direction of veterinarians and only for periods of less than 5 days. Under these conditions, it appears unlikely that quinolone use in veterinary practice will be detrimental to human chemotherapy.


Ofloxacin Enrofloxacin Tylosin Broiler Chick Danofloxacin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Yagisawa M. Development of veterinary new quinolone anti-bacterials. J Vet Med 1994; 47: 241–7Google Scholar
  2. 2.
    Takedayakuhinkogyo. Oral benofloxacin drug, Pipilocin. Juikai 1993; 135: 40–2Google Scholar
  3. 3.
    Takahashi I, Yoshida T, Higashide Y, et al. Susceptibilities of Escherichia coli, Salmonella and Staphylococcus aureus isolated from animals to ofloxacin and commonly used antimicrobial agents. Jpn J Antibiot 1990; 43: 89–99PubMedGoogle Scholar
  4. 4.
    Yamamoto T. Antibacterial activity of Baytril against cattle and swine respiratory pathogens. Doyaku Kenkyu 1992; 46: 18–27Google Scholar
  5. 5.
    Cooper AC, Fuller JR, Fuller MK, et al. In vitro activity of danofloxacin, tylosin and oxytetracycline against mycoplasmas of veterinary importance. Res Vet Sci 1993; 54: 329–34PubMedCrossRefGoogle Scholar
  6. 6.
    Sakaguchi Y, Kouno K, Nakai M, et al. AT-4526, a new quinolone derivative: its in vitro and in vivo antibacterial activity as a veterinary medicine. In: Williams El, editor. Proceedings of XVII World Buiatrics Congress, XXV American Association of Bovine Practitioners Conference. Minnesota: Frontier Printers, Inc 1992; 3: 192–8Google Scholar
  7. 7.
    Raemdonck DL, Tanner AC, Tolling ST, et al. In vitro susceptibility of avian Escherichia coli and Pasteurella multocida to danofloxacin and five other antimicrobials. Avian Dis 1992; 36: 964–7PubMedCrossRefGoogle Scholar
  8. 8.
    Smith IM, Mackie A, Lida J. Effect of giving enrofloxacin in the diet to pigs experimentally infected with Actinobacillus pleuropneumoniae. Vet Rec 1991; 129: 25–9PubMedCrossRefGoogle Scholar
  9. 9.
    Tanner AC, Avakian AP, Barnes HJ, et al. A comparison of danofloxacin and tylosin in the control of induced Mycoplasma gallisepticum infection in broiler chicks. Avian Dis 1993; 37: 515–22PubMedCrossRefGoogle Scholar
  10. 10.
    Migaki TT, Avakian AP, Barnes HJ, et al. Efficacy of danofloxacin and tylosin in the control of mycoplasmosis in chicks infected with tylosin-susceptible or tylosin-resistant field isolates of Mycoplasma gallisepticum. Avian Dis 1993; 37: 508–14PubMedCrossRefGoogle Scholar
  11. 11.
    Jordan FT, Horrocks BK, Jones SK, et al. A comparison of the efficacy of danofloxacin and tylosin in the control of Mycoplasma gallisepticum infection in broiler chicks. J Vet Pharmacol Ther 1993; 16: 79–86PubMedCrossRefGoogle Scholar
  12. 12.
    Kempf I, Gesbert F, Guittet M, et al. Efficacy of danofloxacin in the therapy of experimental mycoplasmosis in chicks. Res Vet Sci 1992; 53: 257–9PubMedCrossRefGoogle Scholar
  13. 13.
    Uchida K, Fujii T, Takayama K, et al. Therapeutic effect and dose response study of danofloxacin on the experimental Escherichia coli infection in broiler chicks. Kachiku Eisei Kenkyu Kaiho 1991; 33: 19–24Google Scholar
  14. 14.
    Kouno K, Sakaguchi Y, Nakai M, et al. AT-4526, a new quinolone derivative: its pharmacokinetics in cats, dogs, pigs and calves. In: Williams El, editor. Proceedings of XVII World Buiatrics Congress, XXV American Association of Bovine Practitioners Conference. Minnesota: Frontier Printers, Inc 1992; 3: 178–84Google Scholar
  15. 15.
    Mann DD, Frame GM. Pharmacokinetic study of danofloxacin in cattle and swine. Am J Vet Res 1992; 53: 1022–6PubMedGoogle Scholar
  16. 16.
    Giles CJ, Magonigle RA, Grimshaw WT, et al. Clinical pharmacokinetics of parenterally administered danofloxacin in cattle. J Vet Pharmacol Ther 1991; 14: 400–10PubMedCrossRefGoogle Scholar
  17. 17.
    Conzelman GM, Babish JG, Davidson JN, et al. Pharmacokinetics of 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(4-ethyl-1-piperazinyl)-3-quinolone-carboxylic acid (BAY Vp 2674) in chickens. Proc West Pharmacol Soc 1987; 30: 393–5PubMedGoogle Scholar
  18. 18.
    Friis C. Penetration of danofloxacin into the respiratory tract tissues and secretions in calves. Am J Vet Res 1993; 54: 1122–7PubMedGoogle Scholar
  19. 19.
    Apley MD, Upson DW. Regional danofloxacin lung tissue concentrations and their relationship to regional pulmonary blood flow in consolidated and nonconsolidated bovine lung. Am J Vet Res 1993; 54: 944–51PubMedGoogle Scholar
  20. 20.
    Apley MD, Upson DW. Lung tissue concentrations and plasma pharmacokinetics of danofloxacin in calves with acute pneumonia. Am J Vet Res 1993; 54: 937–43PubMedGoogle Scholar
  21. 21.
    Friis C. Danofloxacin in calves: pharmacokinetics and penetration into the respiratory tract tissue. Acta Vet Scand Suppl. 1991; 87: 104–6Google Scholar
  22. 22.
    Lekeux P, Art T. Effect of enrofloxacin therapy on shipping fever pneumonia in feedlot cattle. Vet Rec 1988; 123: 205–7PubMedCrossRefGoogle Scholar
  23. 23.
    Yamamoto T, Watanabe K, Horikita T, et al. Therapeutic efficacy of enrofloxacin to swine Actinobacillus pleuropneumoniae infection. Kachiku Shinryo 1992; 352: 19–27Google Scholar
  24. 24.
    Kurose K, Fujiwara M, Yamakawa M, et al. Therapy of suckling calf diarrhea with Baytril injections. Doyaku Kenkyu 1992; 46: 28–35Google Scholar
  25. 25.
    Hoshi K, Ono K, Yoshimura H, et al. Therapeutic effect of Baytril injections on bacterial pneumonia in suckling male calves. Doyaku Kenkyu 1992; 46: 37–45Google Scholar
  26. 26.
    Yamamoto T, Horikita T, Watanabe K, et al. Therapeutic effect of enrofloxacin (Baytril) injections on pleuropneumonia. Doyaku Kenkyu 1992; 46: 8–17Google Scholar
  27. 27.
    Nakamura A. Field trials of enrofloxacin injections. Rinsho Jui 1992; 10: 1960–4Google Scholar
  28. 28.
    Giles CJ, Grimshaw WT, Shanks DJ, et al. Efficacy of danofloxacin in the therapy of acute bacterial pneumonia in housed beef cattle. Vet Rec 1991; 128: 296–300PubMedCrossRefGoogle Scholar
  29. 29.
    Grimshaw WT, Giles CJ, Cooper AC, et al. The efficacy of danofloxacin in the therapy of pneumonia associated with Pasteurella species in housed calves. DTW Dtsch Tierarztl Wochenschr 1990; 97: 529–32PubMedGoogle Scholar
  30. 30.
    Kagota K, Hakogi E, Noma S, et al. AT-4526, a new quinolone derivative: its clinical evaluation on bacterial respiratory disease and diarrrhea in calves. In: Williams EI, editor. Proceedings of XVII World Buiatrics Congress, XXV, American Association of Bovine Practitioners Conference. Minnesota: Frontier Printers, Inc 1992; 3: 185–91Google Scholar
  31. 31.
    Nakagawa M, Kishimoto M, Wakatake S, et al. Bacteriological examination of nasal cavity in bovine respiratory infections and efficacy of AT-4526. Kachiku Shinryo 1992; 348: 5–11Google Scholar
  32. 32.
    Sekine F, Hamana M. Efficacy of new antibacterial quinolone preparation AT-4526 against swine bacterial respiratory infections. Kachiku Shinryo 1992; 348: 13–9Google Scholar
  33. 33.
    Nakamura A, Abe H. Effect of Baytril on colibacillosis in broiler chicks. Doyaku Kenkyu 1993; 47: 17–24Google Scholar
  34. 34.
    Hinz K-H, Rottmann S. Studies in vivo on the efficacy of enrofloxacin against Mycoplasma gallisepticum. Avian Pathology 1990; 19: 511–22PubMedCrossRefGoogle Scholar
  35. 35.
    Sakai T, Suzuki T, Okazaki Y, et al. Therapeutic effect of Baytril on the mixed infection with Mycoplasma gallisepticum and Haemophilus paragallinarum in raising chickens. Doyaku Kenkyu 1992; 45: 28–34Google Scholar
  36. 36.
    Schneider RP, Ericson JF, Lynch MJ, et al. Confirmation of danofloxacin residues in chicken and cattle liver by microbore high-performance liquid chromatography ionization tandem mass spectrometry. Biol Mass Spectrom 1993; 22: 595–9PubMedCrossRefGoogle Scholar
  37. 37.
    Lynch MJ, Rice JR, Ericson JF, et al. Residue depletion studies on danofloxacin in the chicken. J Agricult Food Chem 1994; 42: 289–94CrossRefGoogle Scholar
  38. 38.
    Satake S. Annual changes of drug susceptibility (1983–1992). In: Medical Information System Development Center, editor. Drug susceptibility information 1993. Tokyo: Yakugyo Jihosha, 1993: 45–57Google Scholar
  39. 39.
    Cambau E, Gutmann L. Mechanisms of resistance to quinolones. Drugs 1993; 45 Suppl. 3: 15–23PubMedCrossRefGoogle Scholar
  40. 40.
    Couvalin P. Plasmid-mediated 4-quinolone resistance: a real or apparent absence?. Antimicrob Agents Chemother 1990; 34: 681–4CrossRefGoogle Scholar
  41. 41.
    Nagatake T. The present and the future of new quinolone treatment: clinical internal medicine. Antibiot Chemother 1991; 7: 85–93Google Scholar

Copyright information

© Adis International Limited 1995

Authors and Affiliations

  • Shinichi Nakamura
    • 1
  1. 1.Bioscience Research LaboratoriesDainippon Pharmaceutical Co., LtdSuita, Osaka 564Japan

Personalised recommendations